|
Due Diligence Links
Biomedical Diagnostics,
LLC
Overview | Market Opportunity |
Management Team | Corporate Structure |
Investment
Structure | Address
Biomedical Diagnostics is a joint-venture between
Biotherapies, Inc. and Genesis Bioventures that is developing
proprietary cancer screening products. Its initial product development
effort is the commercialization of the Mammastatin Serum Assay (MSA) as
a risk screening diagnostic for breast cancer.
Mammastatin is a protein that has been found to be present in the breast
tissue of healthy women. In previous research at Biotherapies, it has
been detected in the blood of over 85% of healthy women and absent in
the blood of over 90% of breast cancer patients. That research also
showed that the concentration of Mammastatin not only drops
significantly in women with breast cancer but also in women at high risk
for breast cancer. Biomedical Diagnostics is developing a simple
diagnostic test to detect the level of Mammastatin for the purpose of
measuring a women's risk of developing breast cancer.
The MSA is a blood test that measures Mammastatin levels in serum
samples using monoclonal antibody technology. Data from a clinical study
using the MSA test on blood samples from over 200 women indicates that
there is a consistent difference in Mammastatin levels between healthy
women and breast cancer patients. To date, there has not been a blood
test that is capable of assessing risk for breast cancer prior to
development of this disease, although there are some protein
"markers" that are used to monitor treatment or to suggest
that cancer might already be present. The potential of the MSA test is
to provide a simple blood test that could be capable of much earlier
awareness of the risk of breast cancer so that appropriate monitoring or
preventive therapy can be implemented.
In addition to the development of the MSA test, Biomedical Diagnostics
also has the rights to market the test worldwide and to develop and
market similar risk assessment tests for other related proteins
associated with prostate and ovarian cancer. These tests could identify
patients with a significant risk of developing these diseases prior to
any symptoms appearing and, as a result, could substantially enhance the
opportunities for detecting and treating these cancers earlier.
|
| It has been estimated that 1 in 8 women in the United
States will be diagnosed with breast cancer at some point in their
lifetime, regardless of their family history or other known risk
factors. Based on testing all women over age 40, there are over
50,000,000 women per year in the US alone who could potentially benefit
from having a Mammastatin Serum Assay done as part of their annual
medical check-up. In addition, Biomedical Diagnostics also has the
rights to develop, market and distribute diagnostic screening assays for
prostate and ovarian cancer that are derived from this technology.
|
| Biomedical Diagnostics was founded in November 1998, as a
joint venture between Biotherapies Inc. of Ann Arbor, Michigan and
Genesis Bioventures.
|
| Genesis Bioventures currently holds a 50% ownership in
Biomedical Diagnostics.
|
Biomedical Diagnostics, LLC
5692 Plymouth Road, Suite B
Ann Arbor, Michigan
USA 48105
Tel: (734) 913-9040
Fax: (734) 996-9024
Web: www.bio-diagnostics.com
|
Due Diligence Links
|
Mr. James S. Arthurs, President